ArticleInternational journal of computer assisted radiology and surgery2026
Clinical DVH metrics as a loss function for 3D dose prediction in head and neck radiotherapy.
Article in International journal of computer assisted radiology and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeDeep learning-based three-dimensional (3D) dose prediction is widely used in automated radiotherapy workflows. However, most existing models are trained with voxel-wise regression losses, which are poorly aligned with clinical plan evaluation criteria based on dose-volume histogram (DVH) metrics. This study aims to develop a clinically guided loss formulation that directly optimizes clinically used DVH metrics while remaining computationally efficient for head and neck (H&N) dose prediction.
methodsWe propose a clinical DVH metric loss (CDM loss) that incorporates differentiable D-metrics and surrogate V-metrics, together with a lossless bit-mask region-of-interest (ROI) encoding to improve training efficiency. The method was evaluated on 174 H&N patients using a temporal split (137 training, 37 testing).
resultsCompared with MAE- and DVH curve-based losses, CDM loss substantially improved target coverage and satisfied all clinical constraints. Using a standard 3D U-Net, the PTV Score was reduced from 1.544 (MAE) to 0.491 (MAE + CDM), while OAR sparing remained comparable. Bit-mask encoding reduced training time by 82.2% and lowered GPU memory usage.
conclusionDirectly optimizing clinically used DVH metrics enables 3D dose predictions that are better aligned with clinical treatment planning criteria than conventional voxel-wise or DVH curve-based supervision. The proposed CDM loss, combined with efficient ROI bit-mask encoding, provides a practical and scalable framework for H&N dose prediction.
Indexed as
Identifiers
42593663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.